Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

erippetoe

To: stockdoc77 who wrote (63232)	8/16/2025 12:22:20 AM
From: ghettogoulash	1 Recommendation Read Replies (1) of 63276

SRPT: this rally might have legs. FDA just granted full approval to Precigen’s viral vector-based gene therapy today. In fact, the BLA filed in December was seeking only Accelerated Approval. “Randomized trials are not always needed to approve medical products and this approval is proof of that philosophy,” Vinay Prasad, M.D., the director of the FDA’s Center for Biologics Evaluation and Research, said in a release. “The FDA will always demand the correct clinical study for the specific medical product and disease. Our requirements for products given to tens of millions of healthy people will be different than products given to at most hundreds or thousands of patients with unique diseases.” All we want is a level playing field, A-hole. You too, Makary.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next